Suppr超能文献

在前列腺癌中循环肿瘤细胞的分离和鉴定。

Isolation and characterization of circulating tumor cells in prostate cancer.

机构信息

Division of Hematology and Medical Oncology, Weill Cornell Medical College New York, NY, USA.

出版信息

Front Oncol. 2012 Oct 11;2:131. doi: 10.3389/fonc.2012.00131. eCollection 2012.

Abstract

UNLABELLED

Circulating tumor cells (CTCs) are tumor cells found in the peripheral blood that putatively originate from established sites of malignancy and likely have metastatic potential. Analysis of CTCs has demonstrated promise as a prognostic marker as well as a source of identifying potential targets for novel therapeutics. Isolation and characterization of these cells for study, however, remain challenging owing to their rarity in comparison with other cellular components of the peripheral blood. Several techniques that exploit the unique biochemical properties of CTCs have been developed to facilitate their isolation. Positive selection of CTCs has been achieved using microfluidic surfaces coated with antibodies against epithelial cell markers or tumor-specific antigens such as EpCAM or prostate-specific membrane antigen (PSMA). Following isolation, characterization of CTCs may help guide clinical decision making. For instance, molecular and genetic characterization may shed light on the development of chemotherapy resistance and mechanisms of metastasis without the need for a tissue biopsy. This paper will review novel isolation techniques to capture CTCs from patients with advanced prostate cancer, as well as efforts to characterize the CTCs. We will also review how these analyzes can assist in clinical decision making.

CONCLUSION

The study of CTCs provides insight into the molecular biology of tumors of prostate origin that will eventually guide the development of tailored therapeutics. These advances are predicated on high yield and accurate isolation techniques that exploit the unique biochemical features of these cells.

摘要

未加标签

循环肿瘤细胞(CTCs)是在外周血液中发现的肿瘤细胞,推测来源于已建立的恶性肿瘤部位,并且可能具有转移潜力。CTCs 的分析已被证明是一种有前途的预后标志物,也是识别潜在治疗靶点的来源。然而,由于其在外周血液中其他细胞成分中的稀有性,这些细胞的分离和鉴定仍然具有挑战性。已经开发了几种利用 CTCs 独特生化特性的技术来促进其分离。CTCs 的阳性选择是通过用针对上皮细胞标志物或肿瘤特异性抗原(如 EpCAM 或前列腺特异性膜抗原(PSMA)的抗体涂覆的微流控表面来实现的。分离后,CTCs 的特征分析可能有助于指导临床决策。例如,分子和遗传特征分析可以揭示化疗耐药性的发展和转移机制,而无需组织活检。本文将综述从晚期前列腺癌患者中捕获 CTCs 的新型分离技术,以及对 CTCs 进行特征分析的努力。我们还将回顾这些分析如何协助临床决策。

结论

CTCs 的研究提供了对源自前列腺的肿瘤的分子生物学的深入了解,最终将指导针对这些肿瘤的个体化治疗的发展。这些进展取决于能够利用这些细胞独特生化特性的高产量和准确的分离技术。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0112/3468833/ac9c5dfb882f/fonc-02-00131-g0001.jpg

相似文献

1
Isolation and characterization of circulating tumor cells in prostate cancer.
Front Oncol. 2012 Oct 11;2:131. doi: 10.3389/fonc.2012.00131. eCollection 2012.
6
Identifying cancer origin using circulating tumor cells.
Cancer Biol Ther. 2016 Apr 2;17(4):430-8. doi: 10.1080/15384047.2016.1141839.
10
Isolation of rare circulating tumour cells in cancer patients by microchip technology.
Nature. 2007 Dec 20;450(7173):1235-9. doi: 10.1038/nature06385.

引用本文的文献

1
Clinical significance and heterogeneity of circulating tumor cells and clusters in breast cancer subtypes.
PeerJ. 2025 Jul 9;13:e19703. doi: 10.7717/peerj.19703. eCollection 2025.
2
Nurturing the marriages of urinary liquid biopsies and nano-diagnostics for precision urinalysis of prostate cancer.
Smart Med. 2023 Feb 14;2(1):e20220020. doi: 10.1002/SMMD.20220020. eCollection 2023 Feb.
3
Circulating Tumour Cells Indicate the Presence of Residual Disease Post-Castration in Prostate Cancer Patient-Derived Xenograft Models.
Front Cell Dev Biol. 2022 Apr 13;10:858013. doi: 10.3389/fcell.2022.858013. eCollection 2022.
4
[Recent advances in isolation and detection of circulating tumor cells with a microfluidic system].
Se Pu. 2022 Mar 8;40(3):213-223. doi: 10.3724/SP.J.1123.2021.07009.
7
Association of Monoamine Oxidase A with Tumor Burden and Castration Resistance in Prostate Cancer.
Curr Ther Res Clin Exp. 2020 Oct 28;93:100610. doi: 10.1016/j.curtheres.2020.100610. eCollection 2020.
8
Development and Clinical Prospects of Techniques to Separate Circulating Tumor Cells from Peripheral Blood.
Cancer Manag Res. 2020 Aug 14;12:7263-7275. doi: 10.2147/CMAR.S248380. eCollection 2020.

本文引用的文献

1
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device.
PLoS One. 2012;7(4):e35976. doi: 10.1371/journal.pone.0035976. Epub 2012 Apr 27.
3
Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers.
Phys Biol. 2012 Feb;9(1):016003. doi: 10.1088/1478-3975/9/1/016003. Epub 2012 Feb 3.
4
A fluid biopsy as investigating technology for the fluid phase of solid tumors.
Phys Biol. 2012 Feb;9(1):010301. doi: 10.1088/1478-3975/9/1/010301. Epub 2012 Feb 3.
6
FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE™ platform.
Cancer Genet. 2011 Nov;204(11):589-95. doi: 10.1016/j.cancergen.2011.10.011.
7
Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices.
Biomed Microdevices. 2012 Apr;14(2):401-7. doi: 10.1007/s10544-011-9616-5.
8
Circulating tumor cell isolation and diagnostics: toward routine clinical use.
Cancer Res. 2011 Sep 15;71(18):5955-60. doi: 10.1158/0008-5472.CAN-11-1254. Epub 2011 Sep 6.
9
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas.
Br J Cancer. 2011 Sep 6;105(6):847-53. doi: 10.1038/bjc.2011.294. Epub 2011 Aug 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验